Guggenheim initiated coverage on iCAD with a new price target
$ICAD
Medical/Dental Instruments
Health Care
Guggenheim initiated coverage of iCAD with a rating of Buy and set a new price target of $24.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/18/2022 | Buy → Neutral | Guggenheim | |
| 1/5/2022 | $22.00 → $16.00 | Outperform | Oppenheimer |
| 11/10/2021 | $22.00 → $18.00 | Market Outperform | JMP Securities |
Guggenheim downgraded icad from Buy to Neutral
Oppenheimer reiterated coverage of icad with a rating of Outperform and set a new price target of $16.00 from $22.00 previously
JMP Securities reiterated coverage of icad with a rating of Market Outperform and set a new price target of $18.00 from $22.00 previously
8-K - ICAD INC (0000749660) (Filer)
8-K - ICAD INC (0000749660) (Filer)
10-Q - ICAD INC (0000749660) (Filer)
NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenues increased 14% to $5.4 millionGross Profit Margin of 86%382 Total deals closed in 2024, 42 of which were ProFound CloudProFound Detection V4.0 granted FDA clearanceExpanded global reach with ne
NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064 About iCAD, Inc. iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered
NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft's solutions, this collaboration brings iCAD's ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within th
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G - ICAD INC (0000749660) (Subject)
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C
NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare executive with over 35 years of experience. He is currently the CEO of Spire Health, a leading healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire along with Mr. Doyle's recent companies all achieved measu
NASHUA, N.H., April 17, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Product Officer (CPO) and Michelle Strong as Chief Operations Officer (COO), effective May 1. "As we explore new strategic approaches to execute our mission and expand our impact worldwide, experienced and visionary leadership is critical to the success of our organization. Eric, Vasu, and Michelle bring proven expertise to drive growth, increas
NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenues increased 14% to $5.4 millionGross Profit Margin of 86%382 Total deals closed in 2024, 42 of which were ProFound CloudProFound Detection V4.0 granted FDA clearanceExpanded global reach with ne
NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064 About iCAD, Inc. iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered
NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3 million, up 10% year over yearTotal revenues were $4.2 million, up 4% year over yearGross Profit Margin was 86%, consistent with prior year13 cloud deals closed during the quarter, key wins include: University California San Diego (UCSD) signed a 3-year Cloud deal Charlot